Request for Proposal NIH-NIDDK-O5-05 Preclinical Study of Efficacy in Animal Models of Type 1 Diabetes

Notice Number: NOT-DK-05-009

Key Dates
Release Date: March 2, 2005

Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), (

The purpose of this Notice is to announce the availability of Request for Proposal NIH-NIDDK-05-05 Preclinical Study of Efficacy in Animal Models of Type 1 diabetes. NIDDK is seeking an organization or an institution to perform preclinical studies of potential new therapeutics for the prevention or treatment of Type 1 diabetes. A clinical evaluation is not required at this time. The contractor will work closely with NIDDK project staff and external scientific consultants in designing protocols appropriate for the individual requirements of these compounds. The contractor shall prepare draft protocols with the final design to be approved by the Project Officer. The contractor shall conduct studies of potential therapeutics for the treatment and prevention of Type 1 diabetes as approved by the Project Officer. The contractor shall prepare final study reports in consultation with the Project Officer for submission as Investigational New Drug Applications (IND) to the Food and Drug Administration (FDA) for support of efficacy and/or mechanism of action of the potential new therapeutics.

A contract has not previously been awarded for this work.

The Type 1 Diabetes – Rapid Access to Intervention Development (T1D-RAID) program is designed to assist translation from the research bench to the clinic of novel therapeutic interventions for Type 1 diabetes and its complications. These potential interventions can be either synthetic, natural product or biologic.

T1D-RAID is not a grant mechanism. Approved request to T1D-RAID gain access to the drug development contract resources of the National Cancer Institute’s Development Therapeutics Program (NCI DTP). The output of the use of these resources is provided to the originating investigator and may include GMP synthesized material, formulation research, pharmacological methods of IND-directed toxicology for support of an investigator-held IND application and clinical trials. T1D-RAID does not support clinical trials; it supports the work needed to get ready to do clinical trials.


For questions or further information, contact:

Ms. Marlene Mireles
Contract Specialist
Acquisition Management Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Two Democracy Plaza, Room 781
6707 Democracy Blvd
Bethesda, MD 20892-5456
Phone: 301-594-8831
Fax: 301-480-4226

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.